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 Summary
Aim: The basic assumption of the prevention of cervical cancer is to early detect and treat CIN (cervical intraepithelial 
neoplasia) as well as to prevent recurrence of neoplasia after therapy. This study involved comparison of the cytology 
test value and determination of HPV (human papilloma virus) DNA in women treated for CIN so as to find a sensitive 
and specific marker of disease recurrence. 
Methods: A group of 107 females after CIN treatment underwent 14-month follow-up and regular cytological and 
molecular evaluations. 
Results: Based on the follow-up data the recurrence of CIN was found in 9 females who despite effective therapy 
for the entire follow-up period were HPV positive. Evaluation of value of HR (high risk) - HPV DNA assay used to 
detect CIN showed its 100% sensitivity. 
Conclusion: The HR-HPV DNA assay is likely to be a valuable diagnostic tool facilitating more precise detection of 
recurrent neoplasia risk than cytological test alone. 
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Introduction
Malignant	neoplasms	are	currently	one	of	the	most	serious	
diseases	affecting	people,	and	the	growing	morbidity	and	mortality	
rates	 raise	 in	 consequence	 a	 lot	 of	 concern	 among	 medical	
professionals.	The	employment	of	more	and	more	sophisticated	
diagnostic	methods	and	effective	therapy	will	not	replace	proper	
prophylaxis	which	–	if	used	systematically	and	to	an	appropriate	
extent	 –	 undoubtedly	 contributes	 to	 the	 decreased	 incidence	
of	 malignant	 neoplasms.	 It	 is	 noticeable	 especially	 in	 case	 of	
prophylaxis	of	cervical	cancer.	Cervical	cancer	is	the	second	most	
common	malignancy	in	females	worldwide	[1].	According	to	the	
National	Cancer	Registry	 in	Poland,	 cervical	 cancer	makes	up	
5.2%	of	all	cancers	in	women	and	morbidity	rate	is	the	third	most	
common	one	after	breast	cancer	(21.5%)	and	lung	cancer	(8.2%);	
at	the	same	time	is	the	most	frequent	cancer	of	the	genital	organs	
[1].	The	reason	for	this	unfavorable	situation	lies	in	low	efficacy	
of	programs	against	cancers	of	 this	organ	and	poor	attendance	
rate	 in	 prophylactic	medical	 examinations	 [2].	 Documentation	
of	Human	Papilloma	Virus	 (HPV)	 infection	 in	etiology	of	 this	
disease	gives	an	outstanding	chances	to	prevent	and	early	detect	
cervical	diseases	and	cervical	cancer	[3,4].	Recent	studies	showed	
that	HPV	DNA	assay	combined	with	a	traditional	cytology	may	
lead	to	early	detection	of	both	primary	cervical	neoplasia	as	well	
as	recurrence	of	neoplasia	after	therapy,	decreasing	the	need	for	
colposcopy	and	treatment	[5,	6].	
Study objective
The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 value	 of	 HR-
HPV	DNA	assay	as	a	marker	of	recurrent	disease	in	females	after	
therapy	for	intraepithelial	cervical	neoplasia.	
Study population and design
The	 studied	 material	 included	 pap	 smears	 and	 tissue	
specimens	collected	 from	 the	cervix	 in	107	 females	diagnosed	
at	 the	 Cervical	 Pathophysiology	 Lab	 (CPL)	 of	 the	 University	
Clinical	 Obstetrics	 and	 Gynecological	 Hospital	 in	 Poznan	
between	 June	 2004	 and	October	 2006.	 Females	 were	 referred	
to	the	CPL	due	to	abnormal	pap	smears	(ASCUS,	LSIL,	HSIL)	
[7].	
Each	 subject	 had	 cervical	 biopsy	 under	 colposcopy.	
Histopathological	examinations	of	the	tissue	specimens	revealed	
various	grade	cervical	intraepithelial	neoplasia.	Based	on	those	
results,	3	study	groups	were	distinguished:	32	patients	with	CIN	
I,	43	patients	with	CIN	II,	and	32	patients	with	CIN	III	(mean	
age	31.7,	33.7,	and	35.9	years,	respectively).	Prior	to	the	onset	of	
CIN	treatment	all	patients	had	cytological	samples	collected	from	
the	 cervical	 disk	 and	 canal	 in	 order	 to	 detect	 high	 oncogenic-
risk	HPV	DNA.	This	examination	was	repeated	in	each	woman	
at	2	to	4	months	after	the	therapy.	Control	HPV	DNA	tests	and	
cytological	smears	were	also	performed	at	6-8	and	12-14	months	
after	 treatment.	The	patients	with	abnormal	cytological	 smears	
(ASC-US,	LSIL,	HSIL)	had	another	colposcopy	performed	and	
specimens	collected	for	histopathological	reanalysis.	
The	study	participants	declared	complete	sexual	abstinence	
from	 treatment	 onset	 to	 the	 first	 control	 of	 HR-HPV	 DNA.	
During	 the	 study	 conduct,	 both	 females	 and	 their	 partners	
declared	to	avoid	adulterous	sexual	intercourse	outside	marriage	
or	partnership.	
Human	 papilloma	 virus	 DNA	 was	 determined	 in	 the	
cellular	material	collected	from	the	cervical	disc	and	canal	using	
Amplicor	 HPV	 equipment.	 Amplicor	 HPV	 quality	 test	 used	
amplification	 of	 DNA	 segment	 by	 polymerase	 chain	 reaction	
(PCR)	and	hybridization	of	nucleic	acid	to	detect	genotypes	of	
high	risk	(high	risk	–	HR)	HPV	DNA:	16,	18,	31,	33,	35,	45,	51,	
52,	56,	58,	59	and	68	 in	cervical	canal	cells	drawn	 into	 liquid	
transport	medium.	
The	 Amplicor	 HPV	 test	 simultaneously	 performs	
amplification	of	PCR	of	 the	 searched	HPV	DNA	segment	 and	
B-globin	DNA	(cellular	control).	Amplification	mixture	(Master	
Mix)	contains	DNA	starter	pairs	for	13	high	risk	HPV	genotypes	
and	 B-globins.	 The	 detection	 of	 amplificated	 DNA	 fragments	
(amplicons)	 is	 carried	 out	 using	 oligonucleotide	 probe,	 which	
helps	 to	 independently	 identify	HPV	amplicons	 and	B-globins	
amplicons.	The	use	of	AmpErase	enzyme	limits	the	risk	of	cross	
pollution,	thus	ensuring	a	selective	amplification	of	the	examined	
nucleic	acid.	This	test	provides	repeatability	of	results	and	does	
not	 raise	 interpretative	 doubts,	 having	 high	 clinical	 sensitivity	
and	specificity	of	96	%	[5].
 Streszczenie
Cel pracy: Podstawowym założeniem profilaktyki raka szyjki macicy, jest wczesne wykrycie i leczenie CIN a także 
zapobieganie nawrotom neoplazji po leczeniu. W pracy porównano wartość testu cytologicznego oraz oznaczania 
DNA HPV u kobiet leczonych z powodu CIN w celu poszukiwania czułego i swoistego markera nawrotu procesu 
chorobowego. 
Metoda: 14-miesięcznej obserwacji poddano 107 kobiet po leczeniu CIN, u których regularnie wykonywano ocenę 
cytologiczną i molekularną. 
Wyniki: Nawrót CIN wykryto u 9 obserwowanych kobiet, które mimo skutecznej terapii przez cały okres obserwacji 
były HPV pozytywne. Ocena wartości testu na obecność DNA HPV HR, użytego do wykrycia CIN wykazała 100% 
czułość tej metody. 
Wnioski: Test na obecność DNA HPV HR może być cennym narzędziem diagnostycznym, pozwalającym bardziej 
precyzyjnie niż badanie cytologiczne wykryć ryzyko nawrotu neoplazji. 
 Słowa kluczowe: HPV / neoplazja szyjki macicy / wznowa / CIN /      
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Results
The	 group	 of	 107	 women	 with	 confirmed	 cervical	
intraepithelial	 neoplasia	 of	 various	 severity	 were	 followed-
up:	 32	 patients	with	CIN	 I,	 43	with	CIN	 II	 and	 32	with	CIN	
III.	 Before	 the	 treatment,	 all	 subjects	 were	 HR-HPV	 positive.	
In	 91	 cases	 leep-loop	 conization	 was	 performed,	 10	 subjects	
underwent	cryotherapy	and	in	the	remaining	hysterectomy	was	
carried	 out.	At	 the	 first	 follow-up	 visit	 after	 end	 of	 treatment,	
47	 subjects	 (including	 17	with	CIN	 I,	 19	with	CIN	 II	 and	 11	
with	CIN	 III)	 had	 persistent	HR-HPV	 infection.	 Simultaneous	
cytological	examination	(ASCUS	or	LSIL)	was	abnormal	in	only	
5	 ones.	 Subsequent	 follow-up	 visits	 at	 6-8	 and	 12-14	months	
proved	 persisting	 HR-HPV	 infections	 in	 37	 and	 29	 patients,	
respectively.	
Based	on	the	analysis	of	cytology	results,	at	follow-up	II	and	
III,	persistent	HPV	 infection	was	present	 in	9	and	18	patients,	
respectively.	 Based	 on	 the	 histological	 examinations	 over	 the	
entire	follow-up	period	the	recurrence	of	cervical	intraepithelial	
neoplasia	was	 found	 and	 confirmed	 in	9	 treated	 subjects	 (2	of	
them	were	already	present	during	the	follow-up	II	visit).	Among	
HPV	 negative	 patients,	 there	 was	 no	 recurrent	 CIN	 detected	
or	 diagnosed.	On	 the	 other	 hand,	 despite	 effective	 elimination	
of	 HR-HPV	 during	 treatment,	 9	 women	 were	 reinfected	 with	
HPV	by	their	sexual	partner	and	it	remained	till	 the	end	of	the	
follow-up	period.	The	results	of	statistical	analysis	of	all	women,	
without	 considering	 the	 division	 with	 respect	 to	 neoplasia	
severity,	demonstrated	100%	sensitivity	of	both	diagnostic	tests	
for	detecting	recurrent	CIN	at	follow-up	visits	II	and	III.	
Table I. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at follow-up visits II and III  
after treatment in all participating subjects.  
Table II. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at the follow-up visits I, II and III  
after treatment in subjects with CIN.  
Table III. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at follow-up I, II and III visits  
after treatment in subjects with CIN III.  
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Specificity	of	viral	test	increases	while	specificity	of	cytology	
test	decreases	with	the	time	lapse	after	treatment.
Statistical	analysis	of	HPV	DNA	test	in	women	with	CIN	II	
showed	significantly	higher	sensitivity	of	 this	 test	at	 follow-up	
visit	I	and	II	as	compared	to	the	one	of	PAP	test.	As	opposed	to	
HPV	DNA	 test	 specificity	of	 cytological	 test	 for	 follow-ups	 is	
slightly	higher.
Statistical	analysis	of	HPV	DNA	test	in	women	with	CIN	III	
showed	100%	sensitivity	both	at	I,	II	and	III	follow-up	visits	after	
treatment.	Cytology	test	had	100%	sensitivity	only	at	the	follow-
up	III	visit	after	treatment.	In	turn,	specificity	of	both	tests	was	
similar	to	the	study	group	with	CIN	II.
Discussion
Each	time	before	qualification	for	treatment	the	test	for	HPV	
DNA	oncogenic	 type	was	done.	Regarding	 the	study	objective	
only	women	with	cervical	intraepithelial	neoplasia	and	positive	
test	result	for	HR-HPV	DNA.	Results	regarding	the	first	detection	
for	virus	genetic	material	after	 therapy	pointed	out	 that	during	
2	 to	4	months	after	 the	end	of	 therapy	human	papilloma	virus	
persisted	in	45/107	(42%)	followed-up	women.	It	seems	to	be	of	
crucial	importance	that	in	4	of	6	patients	with	suspected	persistent	
neoplasia,	in	whom	–	according	to	histopathological	report	–	it	is	
beyond	certainty	as	regard	the	complete	the	excision	of	neoplastic	
epithelium	due	to	material	fragmentation	thus	resulting	in	positive	
result	of	HPV	DNA	test	at	first	 follow-up	visit	after	 treatment.	
In	 spite	of	 secondary	exclusion	of	CIN	 treatment	 failure,	viral	
infection	persisted	in	these	4	patients	on	subsequent	follow-ups.	
Similar	 relationship	was	described	by	Nagai	 in	5	patients	with	
persistent	 cervical	 intraepithelial	 neoplasia	 selected	 out	 of	 56	
females	treated	for	CIN	[8].	Likewise,	Nobbenhuis	demonstrated	
high,	though	not	full,	correlation	between	persistent	neoplasia	and	
HR-HPV	DNA	identifying	genetic	material	of	oncogenic	types	
of	HPV	 in	27	of	29	 inefficiently	 treated	women	 [9].	Attention	
should	be	drawn	to	the	fact	that	only	2	subjects	with	persistent	
cervical	intraepithelial	neoplasia	after	therapy	had	negative	HR-
HPV	DNA	molecular	test.	There	are	also	some	separate	reports	
on	much	 weaker	 relationship	 between	 persistent,	 ineffectively	
treated	CIN	and	presence	of	HPV	in	the	specimen	collected	from	
the	cervical	canal.	Acladious	et	al.	demonstrated	presence	of	HR-
HPV	DNA	only	in	22	of	47	women	ineffectively	treated	for	CIN	
and	diagnosed	with	persistent	neoplasia	[10].	Paraskevaidis	et	al.	
in	a	cross-sectional	analysis	of	11	multicenter	studies	addressing	
correlation	 between	 persistent	 neoplasia	 and	 chronic	 HPV	
infection	maintained	after	ineffective	treatment	showed	presence	
of	HR-HPV	DNA	 in	 82.8%	 of	women	 in	whom	CIN	 therapy	
failed	[11,	12].	
Our	 study	 involving	 107	 females	 treated	 for	 CIN	 and	
followed	 up	 from	 a	 period	 prior	 to	 the	 treatment	 and	 up	 to	 at	
least	 12-14	months	 after	 its	 end	–	 recurrent	CIN	was	detected	
and	diagnosed	in	9	of	107	(8.4%)	subjects.	According	to	Angel	
Chao	et	al.	the	risk	of	recurrence	of	intraepithelial	neoplasia	in	
women	treated	previously	for	CIN	of	different	severity,	affects	
10.3%	of	patients	[13].	It	was	estimated	by	Flannely	et	al.	 that	
an	 average	 risk	 of	 having	 recurrent	 CIN	 refers	 to	 about	 10%	
of	 women	 during	 2	 years	 after	 the	 end	 of	 therapy	 [14].	 This	
author	 observed	 765	 females	 who	 underwent	 ablation	 of	 CIN	
and	who	afterwards	were	 followed-up	 for	3	years	 [14].	Sarian	
et	al.	performed	an	analysis	of	107	females	treated	for	cervical	
intraepithelial	neoplasia	[15].	Twelve-month	follow-up	revealed	
recurrence	of	CIN	in	10	(11.2%)	of	treated	women.	In	our	study,	
the	 recurring	 disease	 was	 accompanied	 to	 a	 great	 extent	 by	
persistent	viral	infection	in	patients	in	whom	CIN	treatment	did	
not	eliminate	it.	The	high	likelihood	of	such	etiology	of	recurrent	
CIN	was	observed	and	confirmed	using	HR-HPV	DNA	assay	(in	
cervical	 samples)	 in	 7	 subjects,	who	 had	 the	 first	 check-up	 at	
months	2-4	after	the	treatment	when	they	refrained	from	sexual	
intercourse.	Only	in	2	of	9	individuals,	who	had	recurrent	CIN,	
apart	from	the	first	check-up	the	viral	infection	was	also	detected	
during	subsequent	ones.	In	those	patients	the	first	HR-HPV	DNA	
test	scored	negative.	Also	according	to	other	authors	all	cases	of	
recurrent	neoplasia	seem	to	concern	women,	who	had	HR-HPV	
DNA	identified	at	follow-up	after	CIN	therapy	[14,	15].	
No	studies	are	available	so	far	attempting	to	explain	whether	
HR-HPV	DNA	presence	results	from	persistent	infection	or	is	a	
secondarily	acquired	infection	from	a	sexual	partner	during	follow-
up	after	therapy	for	CIN.	These	studies	showed	the	development	
of	 recurring	 cervical	 intraepithelial	 neoplasia	 only	 in	 females	
treated	for	CIN	II	and	CIN	III.	It	is	typical	that	in	females	treated	
for	CIN	II,	recurrent	disease	was	diagnosed	in	6	patients	all	of	
which	could	be	classified	as	CIN	I	 typical	changes.	It	 is	worth	
noting	that	all	women	with	secondary	infection	confirmed	during	
the	 follow-up	had	 recurrent	 neoplasia,	which	was	 documented	
during	 the	 last	 third	 follow-up	 visit.	 Three	 cases	 of	 recurrent	
disease	were	detected	 in	 the	 female	group	 treated	 for	CIN	 III.	
Only	one	patient	had	low-grade	neoplasia	confirmed	during	the	
third	follow-up	visit.	The	remaining	two	patients	were	diagnosed	
with	recurrent	disease	during	the	second	and	the	third	follow-up	
related	to	CIN	II	and	preinvasive	cervical	carcinoma-like	lesion,	
respectively.	It	should	be	highlighted	that	the	cases	of	recurrent	
neoplsia	 in	 this	 group	occurred	 only	 in	women	with	HR-HPV	
infection	persisted	after	treatment.	The	observations	made	could	
be	of	great	practical	importance	with	respect	to	planning	disease	
monitoring	after	CIN	treatment	and	determining	the	schedule	for	
follow-up	HR-HPV	DNA	test	as	a	 relapse	marker.	Taking	 into	
account	 the	 fact	 that	 in	 followed-up	women	referred	with	CIN	
it	is	likely	that	the	source	of	positive	HPV	test	will	be	persistent	
or	acquired	infection.	We	have	to	remember,	that	any	of	sexually	
transmitted	disease	may	be	a	risk	factor	of	acquire	HPV	infection	
[16,	17,	18].	
As	a	result,	a	test	should	be	ordered	to	identify	virus	genetic	
material	during	the	first	follow-up	visit	after	treatment	and	at	least	
12	months	after	treatment	completion	[19].	Provided	that	the	first	
follow-up	visit	takes	place	in	a	patient	who	did	not	have	sexual	
contact,	a	positive	result	of	HR-HPV	DNA	test	identifies	subjects	
with	persistent	infection.	The	second	test	performed	after	at	least	
12	months	confirms	persistent	infection	in	HR-HPV	DNA	positive	
women	in	the	first	examination	or	identifies	secondarily	infection	
in	women	negative	at	the	first	follow-up	after	treatment.	In	our	
studies	it	was	proved	that	both	sources	of	HR-HPV	infection	may	
contribute	to	CIN	recurrence.	Similarly,	the	studies	of	Kreimer	
and	Sarian	showed	that	none	of	the	followed-up	HR-HPV	DNA	
negative	 females	 after	 CIN	 treatment	 had	 recurrent	 disease.	
Sarian	 et	 al.	 revealed	 that	 11	 of	 107	 subjects	 had	 recurrent	
cervical	intraepithelial	neoplasia	due	to	CIN	II	or	CIN	III	[15].	
Most	recurrent	diseases	involved	high-grade	neoplasia	confirmed	
in	 9	 women.	 The	 remaining	 two	 patients	 had	 medium-grade	
neoplasia.	Molecular	 tests	 for	HR-HPV	DNA	were	positive	 in	
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all	women	who	experienced	recurrent	neoplasia	following	CIN	
treatment	[15].	Kreimer	et	al.	came	to	similar	conclusions.	They	
presented	34	recurrences	of	CIN	during	24-month	follow-up	in	
607	treated	subjects.	Again,	all	recurrences	were	documented	in	
HR-HPV	DNA	positive	women	in	cervical	material	[20].	What	
raises	a	great	 interest	 is	 the	comparison	of	 the	effectiveness	of	
HR-HPV	DNA	 test	 between	our	 studies	 and	 those	 of	Kreimer	
carried	out	in	the	comparable	study	groups.
The	 studies	 in	 previously	 treated	 CIN	 patients	 performed	
in	order	to	detect	and	diagnose	another	recurring	neoplasia,	the	
sensitivity	was	100%	both	with	respect	to	viral	and	cytological	
diagnostics	 of	 diagnostics	 used	 successively	 at	 the	 follow-up	
visits	II	and	III.	These	results	were	also	confirmed	by	Kreimer	
et	al.	who	demonstrated	100%	sensitivity	 for	both	 tests	during	
the	 first	 follow-up	 visit	 after	 treatment	 and	 its	 values	 for	
cytodiagnostics	 and	 molecular	 test	 detecting	 HR-HPV	 DNA	
which	 remained	 unchanged	 until	 the	 end	 of	 12-month	 follow-
up	 [20].	Number	of	 investigators	determined	 the	 sensitivity	of	
HR-HPV	DNA	test	as	100%	in	identifying	development	of	CIN	
in	women	 after	 neoplasia	 treatment	 [8,21].	Other	 studies	with	
analogous	examinations	results	showed	slightly	lower	sensitivity	
of	 HR-HPV	 DNA	 test	 as	 opposed	 to	 100%	 presented	 in	 this	
study.	On	the	basis	of	data	gathered	during	the	follow-up	of	the	
larger	group	of	females	Nobbenhuis	and	Paraskevaidis	showed	
93%	sensitivity	of	HR-HPV	DNA	test	in	detecting	recurrence	of	
CIN	[9,	11,	12].	
In	our	 studies	66.7%	and	78%	specificity	was	obtained	at	
follow	up	visit	II	and	III,	respectively,	in	molecular	diagnostics	
of	 recurrent	 CIN	 in	 females	 previously	 treated	 for	 neoplasia.	
It	 should	be	added	 that	 the	percentage	of	negative	 tests	 results	
for	 HR-HPV	DNA	 in	 treated	 healthy	 subjects	 increases	 along	
with	 follow-up	 duration.	 In	 the	 available	 literature,	 individual	
investigators	present	different	specificity	of	 the	HR-HPV	DNA	
test	as	a	method	for	diagnosing	development	of	CIN	recurrence	in	
treated	women.	Lin	et	al.	monitored	75	subjects	after	treatment	of	
CIN	and	as	a	result	gained	48%	specificity	for	viral	diagnostics	in	
detection	of	recurrent	disease	[21].	Specificity	of	HR-HPV	DNA	
tests	 for	CIN	 detection	 given	 by	 other	 authors	 are	 as	 follows:	
88%-Nagai,	86%-Nobbenhuis,	and	84%-Paraskevaidis	[8,	9,	11,	
12].	
In	this	study,	an	increase	of	specificity	with	respect	to	viral	
diagnostics	 is	 parallel	 with	 gradual	 decrease	 in	 specificity	 for	
cytodiagnostics	–	from	93.3%	at	the	first	follow-up	visit	to	89%	
at	the	second	one.	Based	on	these	observations	there	is	the	need	
for	oncologic	follow-up	in	subjects	treated	for	CIN	for	more	than	
only	12	months.	Diagnostic	value	of	HR-HPV	DNA	molecular	
test,	 as	 a	 method	 of	 detection	 of	 recurrent	 CIN	 in	 previously	
treated	women,	 increases	 along	with	 time	 and	 seems	 to	 be	 of	
great	 significance	during	baseline	 follow-up	and	 in	 the	 second	
year	after	treatment.	
An	attention	should	be	drawn	to	significance	of	initial	viral	
test	for	prediction	of	cervical	intraepithelial	neoplasia	in	females	
receiving	 effective	 treatment	 of	 CIN,	 who	 however	 were	 not	
cured	of	 viral	 infection	or	 acquired	 secondary	 infection,	 as	 all	
women	who	experienced	recurrent	CIN	were	HPV	DNA	positive	
at	the	second	follow-up	after	treatment.	A	significant	fact	is	that	
7	of	9	subjects	with	CIN	recurrence	had	HR-HPV	DNA	detected	
at	the	first	follow-up	visit	after	treatment	for	neoplasia.
Conclusion
The	HR-HPV	DNA	assay	is	likely	to	be	a	valuable	diagnostic	
tool	facilitating	more	precise	detection	of	recurrent	neoplasia	risk	
than	cytological	test	alone.
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